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acted as the 'gold' standard test against which the history of varicella was assessed. A total of 637 children entered the study from Yugoslavia (274) , Kosovo (97) , East Africa (155), Vietnam (40) , Iraq/Kurdistan (36) , and the Caribbean (35).
Study design
The basis of the analysis was a diagnostic study, which was conducted in a single international clinic. The patients were not followed up since the study assessed the prevalence of varicella and the accuracy of history as a predictor, at a single point in time. The health assessment of the patients did, however, require two visits. The time between these visits was not reported.
Analysis of effectiveness
The analysis was based on the history of varicella, and whether varicella antibodies were present in a given individual. The primary outcomes were: the prevalence of the varicella antibody; the threshold prevalence beyond which it is more cost-effective to test than to immunise without testing; the positive predictive value (PPV) of history; and the negative predictive value (NPV) of history.
The prevalence of the varicella antibody was assessed in terms of age and country of origin, to avoid the impact of these confounding factors.
Effectiveness results
The critical value of antibody prevalence was 34% in children aged less than 13 years old, and 17% in children aged at least 13 years old.
The authors reported that the critical value was sensitive to variation in compliance. 
Clinical conclusions
In all countries of origin, the prevalence was less than 34% in children aged 1 to 4 years. Therefore, the optimal strategy was to immunise without serotesting. In all countries of origin, the prevalence was greater than 34% in children aged 5 to 12 years, and greater than 17% in children aged 13 to 20 years. Therefore, serotesting was the optimal strategy for both age groups. The authors concluded "the PPV of a positive history was high among children in all regions except Vietnam" and the NPV was a "poor indicator of the absence of varicella antibodies".
Modelling
A model described by Plans Rubio (see Other Publications of Related Interest) was used to determine a prevalence threshold for the varicella antibody, above which it is more cost-effective to test for the antibody than to immunise without testing.
Methods used to derive estimates of effectiveness
The authors made assumptions to supplement the effectiveness estimates.
Estimates of effectiveness and key assumptions
The authors assumed that the attack rate of varicella was 90% in susceptible individuals. They also assumed that the efficacy of one dose of vaccine was 70 to 98% in children aged under 13 years, and 89% in children aged 13 years or older.
Measure of benefits used in the economic analysis
No summary measure of benefits was estimated. The study was therefore classified as a cost-consequences analysis.
Direct costs
The perspective adopted for the cost analysis was not stated, although the costs seem to have been estimated from the perspective of the hospital. No discounting was used, but it was unnecessary as the costs estimated were those incurred immediately in the vaccination process (i.e. screening, vaccination and vaccine administration). The unit costs were presented separately and were derived from actual data. The screening cost was the cost at the Boston Medical Center, while the vaccination cost was based on the Centre for Disease Control contract price. The authors assumed a mean disease cost for children aged younger 13 years and another for children aged 13 or older. The prices were measured between March 1996 and January 2000. However, a price year was not reported. The authors used their cost estimates in a model to estimate the prevalence threshold above which it was more cost-effective to test for the antibody than to immunise without testing. No overall costs of vaccination or immunisation were reported.
Statistical analysis of costs
No statistical analysis of the costs was reported.
Indirect Costs
The indirect costs were not estimated. These were not relevant if the perspective adopted in the analysis was that of the hospital.
